Drug Profile
AR 26
Alternative Names: AR26Latest Information Update: 22 Feb 2022
Price :
$50
*
At a glance
- Originator Arbor Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Psychiatric disorders
Most Recent Events
- 22 Feb 2022 Discontinued - Phase-II for Psychiatric disorders (unspecified route)
- 12 Oct 2016 Phase-II clinical trials in Psychiatric disorders (unspecified route) (Arbor Pharmaceuticals pipeline, October 2016)